Drugs / JS006
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05061628 | Apr 2021 → Apr 2023 | metastatic neoplasm | Shanghai Junshi Bioscience Co., Ltd. | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT05650203 Background | Mar 2023 → Oct 2025 | cancer-related condition | Shanghai Junshi Bioscience Co., Ltd. | Withdrawn | No outcome recorded Stop: Business |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JS006 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05650203 ↗ |
| Action | Inhibit | “Anti-TIGIT” NCT05061628 ↗ |
| Modality | Monoclonal antibody | “Recombinant Humanized Anti-TIGIT Monoclonal Antibody” NCT05061628 ↗ |
| Route | Intravenous | “IV infusion” NCT05061628 ↗ |
| Target | TIGIT | “Anti-TIGIT” NCT05061628 ↗ |